CytomX Therapeutics, Inc.

Equities

CTMX

US23284F1057

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:33:17 2024-05-21 am EDT			5-day change	1st Jan Change
1.905 ^USD	-0.78%		-1.80%	+22.90%

May. 09	BMO Capital Adjusts Price Target on CytomX Therapeutics to $3.59 From $3.25, Maintains Market Perform Rating	MT
May. 09	Wedbush Upgrades CytomX Therapeutics to Outperform From Neutral, Adjusts Price Target to $8 From $3	MT

CytomX Therapeutics, Inc. Announces Resignation of Rachel W. Humphrey as Senior Vice President and Chief Medical Officer

August 22, 2019 at 05:20 pm EDT

On August 19, 2019, it was determined that Rachel W. Humphrey, M.D., Senior Vice President and Chief Medical Officer of CytomX Therapeutics, Inc. (the “Company”), would leave her position and employment with the Company, effective August 19, 2019.

Latest news about CytomX Therapeutics, Inc.

BMO Capital Adjusts Price Target on CytomX Therapeutics to $3.59 From $3.25, Maintains Market Perform Rating	May. 09	MT
Wedbush Upgrades CytomX Therapeutics to Outperform From Neutral, Adjusts Price Target to $8 From $3	May. 09	MT
Earnings Flash (CTMX) CYTOMX THERAPEUTICS Reports Q1 Revenue $41.5M	May. 08	MT
Transcript : CytomX Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024	May. 08
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)	May. 08	CI
CytomX Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
CytomX Therapeutics, Inc. Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with Keytruda® (pembrolizumab)	May. 07	CI
Jefferies Upgrades CytomX Therapeutics to Buy, Price Target at $8	May. 06	MT
JPMorgan Upgrades CytomX Therapeutics to Neutral From Underweight	Apr. 22	MT
CytomX Therapeutics, Inc. Announces First Patient Dosed with CX-2051, A Conditionally Activated EpCAM-Directed ADC, in A Phase 1 Study in Patients with Advanced Solid Tumors	Apr. 08	CI
CytomX Therapeutics, Inc. Appoints Dr. Zhen Su to Board of Directors	Mar. 21	CI
CytomX Therapeutics, Inc. Announces Milestone Achievement in Prospective T-Cell Engaging Bispecific Collaboration with Astellas	Mar. 18	CI
Transcript : CytomX Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 11:45 AM	Mar. 14
BMO Capital Adjusts CytomX Therapeutics Price Target to $3.25 From $3.30, Maintains Market Perform Rating	Mar. 12	MT
North American Morning Briefing : Inflation Data Back in the Spotlight	Mar. 12	DJ
Stocks to Watch : Oracle, Mission Produce, CytomX Therapeutics	Mar. 11	DJ
CytomX Therapeutics Shares Fall 19% After Bristol Myers Squibb Decides Not to Continue Developing Candidate	Mar. 11	DJ
Transcript : CytomX Therapeutics, Inc., Q4 2023 Earnings Call, Mar 11, 2024	Mar. 11
Earnings Flash (CTMX) CYTOMX THERAPEUTICS Reports Q4 Revenue $26.6M, vs. Street Est of $21.2M	Mar. 11	MT
CytomX Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 11	CI
CytomX Therapeutics, Inc. Announces FDA Clearance of IND Applications for CX-2051, a Probody Antibody Drug Conjugate Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b	Jan. 24	CI
Transcript : CytomX Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 05:15 PM	Jan. 10
Wedbush Lifts CytomX Therapeutics' PT to $3 From $2, Says Focused Pipeline Moving Forward; Keeps Neutral Rating	Nov. 09	MT
North American Morning Briefing : Traders Await -2-	Nov. 09	DJ
Transcript : CytomX Therapeutics, Inc., Q3 2023 Earnings Call, Nov 07, 2023	Nov. 07

Chart CytomX Therapeutics, Inc.

Duration

Period

More charts

Company Profile

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) with potential applicability across multiple EpCAM-expressing epithelial cancers.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for CytomX Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.92 USD

Average target price

5.068 USD

Spread / Average Target

+163.96%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CYTOMX THERAPEUTICS, INC.	+22.90%	150M
VERTEX PHARMACEUTICALS INCORPORATED	+9.62%	115B
REGENERON PHARMACEUTICALS, INC.	+13.22%	107B
BIONTECH SE	-13.40%	22.31B
ARGENX SE	-3.41%	21.6B
BEIGENE, LTD.	-5.71%	18.23B
WUXI APPTEC CO., LTD.	-38.57%	17.62B
NEUROCRINE BIOSCIENCES, INC.	+7.91%	14.26B
SAREPTA THERAPEUTICS, INC.	+34.43%	12.37B
LEGEND BIOTECH CORPORATION	-26.76%	8.28B

Bio Therapeutic Drugs